Abionyx Pharma annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Abionyx Pharma R&D Spending Growth & History (ABNX)
Abionyx Pharma's r&d spending was €1.5M for fiscal 2025.
View full Abionyx Pharma company overviewAbionyx Pharma annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €1.5M | −€382,000 | −20.11% |
| 2024 | 2024-12-31 | €1.9M | €382,000 | +25.16% |
| 2023 | 2023-12-31 | €1.5M | €411,000 | +37.13% |
| 2022 | 2022-12-31 | €1.1M | −€2.7M | −71.16% |
| 2021 | 2021-12-31 | €3.8M | €2.1M | +126.03% |
| 2020 | 2020-12-31 | €1.7M | €954,000 | +128.23% |
| 2019 | 2019-12-31 | €744,000 | — | — |
Abionyx Pharma r&d spending trends
Over the last five fiscal years, Abionyx Pharma's r&d spending decreased from €1.7M to €1.5M, a change of −€180,000.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
reported R&D expense
TickerStat standardizes research and development expense reported in company official filings, including the software-specific standardized R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Abionyx Pharma source filings ↗